Literature DB >> 26559972

A Novel Function of Molecular Chaperone HSP70: SUPPRESSION OF ONCOGENIC FOXM1 AFTER PROTEOTOXIC STRESS.

Marianna Halasi1, Renáta Váraljai2, Elizaveta Benevolenskaya2, Andrei L Gartel3.   

Abstract

The oncogenic transcription factor FOXM1 is overexpressed in the majority of human cancers, and it is a potential target for anticancer therapy. We identified proteasome inhibitors as the first type of drugs that target FOXM1 in cancer cells. Here we found that HSP90 inhibitor PF-4942847 and heat shock also suppress FOXM1. The common effector, which was induced after treatment with proteasome and HSP90 inhibitors or heat shock, was the molecular chaperone HSP70. We show that HSP70 binds to FOXM1 following proteotoxic stress and that HSP70 inhibits FOXM1 DNA-binding ability. Inhibition of FOXM1 transcriptional autoregulation by HSP70 leads to the suppression of FOXM1 protein expression. In addition, HSP70 suppression elevates FOXM1 expression, and simultaneous inhibition of FOXM1 and HSP70 increases the sensitivity of human cancer cells to anticancer drug-induced apoptosis. Overall, we determined the unique and novel mechanism of FOXM1 suppression by proteasome inhibitors.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  70-kD heat shock protein (Hsp70); FOXM1; anticancer drug; cell death; gene expression; protein-protein interaction

Mesh:

Substances:

Year:  2015        PMID: 26559972      PMCID: PMC4697151          DOI: 10.1074/jbc.M115.678227

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

1.  Thiostrepton, proteasome inhibitors and FOXM1.

Authors:  Andrei L Gartel
Journal:  Cell Cycle       Date:  2011-12-15       Impact factor: 4.534

Review 2.  Inhibition of HSP70: a challenging anti-cancer strategy.

Authors:  Anastasia R Goloudina; Oleg N Demidov; Carmen Garrido
Journal:  Cancer Lett       Date:  2012-06-28       Impact factor: 8.679

Review 3.  Inhibitors of the heat shock response: biology and pharmacology.

Authors:  Marissa V Powers; Paul Workman
Journal:  FEBS Lett       Date:  2007-05-25       Impact factor: 4.124

4.  Inference of transcriptional regulation in cancers.

Authors:  Peng Jiang; Matthew L Freedman; Jun S Liu; Xiaole Shirley Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-08       Impact factor: 11.205

5.  Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells.

Authors:  Andrew Fribley; Qinghua Zeng; Cun-Yu Wang
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

6.  Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor.

Authors:  Vladimir V Kalinichenko; Michael L Major; Xinhe Wang; Vladimir Petrovic; Joseph Kuechle; Helena M Yoder; Margaret B Dennewitz; Brian Shin; Abhishek Datta; Pradip Raychaudhuri; Robert H Costa
Journal:  Genes Dev       Date:  2004-04-01       Impact factor: 11.361

7.  Hsp70 silencing with siRNA in nanocarriers enhances cancer cell death induced by the inhibitor of Hsp90.

Authors:  Mirela Matokanovic; Karmela Barisic; Jelena Filipovic-Grcic; Dusica Maysinger
Journal:  Eur J Pharm Sci       Date:  2013-04-10       Impact factor: 4.384

8.  Induction of heat shock protein 70 (Hsp70) by proteasome inhibitor MG 132 protects articular chondrocytes from cellular death in vitro and in vivo.

Authors:  Laurent Grossin; Stéphanie Etienne; Nadège Gaborit; Astrid Pinzano; Christel Cournil-Henrionnet; Catherine Gerard; Elisabeth Payan; Patrick Netter; Bernard Terlain; Pierre Gillet
Journal:  Biorheology       Date:  2004       Impact factor: 1.875

Review 9.  Targeting FOXM1 in cancer.

Authors:  Marianna Halasi; Andrei L Gartel
Journal:  Biochem Pharmacol       Date:  2012-10-24       Impact factor: 5.858

10.  ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance.

Authors:  Julie Millour; Natalia de Olano; Yoshiya Horimoto; Lara J Monteiro; Julia K Langer; Rosa Aligue; Nabil Hajji; Eric W F Lam
Journal:  Mol Cancer Ther       Date:  2011-04-25       Impact factor: 6.261

View more
  15 in total

1.  Nuclear FOXM1 drives chemoresistance in AML.

Authors:  I Khan; M Halasi; M F Zia; P Gann; S Gaitonde; N Mahmud; A L Gartel
Journal:  Leukemia       Date:  2016-10-03       Impact factor: 11.528

Review 2.  FOXM1 in Cancer: Interactions and Vulnerabilities.

Authors:  Andrei L Gartel
Journal:  Cancer Res       Date:  2017-06-05       Impact factor: 12.701

Review 3.  YcaO-Dependent Posttranslational Amide Activation: Biosynthesis, Structure, and Function.

Authors:  Brandon J Burkhart; Christopher J Schwalen; Greg Mann; James H Naismith; Douglas A Mitchell
Journal:  Chem Rev       Date:  2017-03-03       Impact factor: 60.622

4.  Formation of Tankyrase Inhibitor-Induced Degradasomes Requires Proteasome Activity.

Authors:  Nina Marie Pedersen; Tor Espen Thorvaldsen; Sebastian Wolfgang Schultz; Eva Maria Wenzel; Harald Stenmark
Journal:  PLoS One       Date:  2016-08-02       Impact factor: 3.240

5.  Honokiol is a FOXM1 antagonist.

Authors:  Marianna Halasi; Ben Hitchinson; Binal N Shah; Renáta Váraljai; Irum Khan; Elizaveta V Benevolenskaya; Vadim Gaponenko; Jack L Arbiser; Andrei L Gartel
Journal:  Cell Death Dis       Date:  2018-01-24       Impact factor: 8.469

6.  The Novel Methylation Biomarker SCARA5 Sensitizes Cancer Cells to DNA Damage Chemotherapy Drugs in NSCLC.

Authors:  Qi Peng; Yan Liu; Xuehua Kong; Jie Xian; Lin Ye; Li Yang; Shuliang Guo; Yan Zhang; Lan Zhou; Tingxiu Xiang
Journal:  Front Oncol       Date:  2021-06-04       Impact factor: 6.244

7.  Novel FOXM1 inhibitor identified via gene network analysis induces autophagic FOXM1 degradation to overcome chemoresistance of human cancer cells.

Authors:  Mikhail S Chesnokov; Marianna Halasi; Soheila Borhani; Zarema Arbieva; Binal N Shah; Rick Oerlemans; Irum Khan; Carlos J Camacho; Andrei L Gartel
Journal:  Cell Death Dis       Date:  2021-07-14       Impact factor: 9.685

Review 8.  Therapeutic Vulnerabilities of Transcription Factors in AML.

Authors:  Irum Khan; Elizabeth E Eklund; Andrei L Gartel
Journal:  Mol Cancer Ther       Date:  2020-11-06       Impact factor: 6.009

Review 9.  Regulation of the master regulator FOXM1 in cancer.

Authors:  Guo-Bin Liao; Xin-Zhe Li; Shuo Zeng; Cheng Liu; Shi-Ming Yang; Li Yang; Chang-Jiang Hu; Jian-Ying Bai
Journal:  Cell Commun Signal       Date:  2018-09-12       Impact factor: 5.712

10.  FOXM1 contributes to treatment failure in acute myeloid leukemia.

Authors:  Irum Khan; Marianna Halasi; Anand Patel; Rachael Schultz; Nandini Kalakota; Yi-Hua Chen; Nathan Aardsma; Li Liu; John D Crispino; Nadim Mahmud; Olga Frankfurt; Andrei L Gartel
Journal:  JCI Insight       Date:  2018-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.